Hubbry Logo
TiHKALTiHKALMain
Open search
TiHKAL
Community hub
TiHKAL
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
TiHKAL
TiHKAL
TiHKAL
View on Wikipedia
from Wikipedia

TiHKAL: The Continuation is a 1997 book written by Alexander Shulgin and Ann Shulgin about a family of psychoactive drugs known as tryptamines.[1][2] A sequel to PiHKAL: A Chemical Love Story, TiHKAL is an acronym that stands for "Tryptamines I Have Known and Loved".[1][2]

Key Information

Content

[edit]

TIHKAL, much like its predecessor PIHKAL, is divided into two parts. The first part, for which all rights are reserved, begins with a fictionalized autobiography, picking up where the similar section of PIHKAL left off; it then continues with a collection of essays on topics ranging from psychotherapy and the Jungian mind to the prevalence of DMT in nature, ayahuasca and the War on Drugs. The second part of TIHKAL, which may be conditionally distributed for non-commercial reproduction (see § External links, below), is a detailed synthesis manual for 55 psychedelic compounds (many discovered by Alexander Shulgin himself), including their chemical structures, dosage recommendations, and qualitative comments. Shulgin has made the second part freely available on Erowid while the first part is available only in the printed text.

As with PIHKAL, the Shulgins were motivated to release the synthesis information as a way to protect the public's access to information about psychedelic compounds, a goal Alexander Shulgin has noted many times.[3] Following a raid of his laboratory in 1994 by the United States DEA,[4] Richard Meyer, spokesman for DEA's San Francisco Field Division, stated that "It is our opinion that those books [referring to the previous work, PIHKAL] are pretty much cookbooks on how to make illegal drugs. Agents tell me that in clandestine labs that they have raided, they have found copies of those books."

Tryptamines listed

[edit]
# Substance Chemical name
1 AL-LAD 6-Allyl-N,N-diethyl-NL
2 DBT N,N-Dibutyl-T
3 DET N,N-Diethyl-T
4 DiPT N,N-Diisopropyl-T
5 α,O-DMS 5-Methoxy-α-methyl-T
6 DMT N,N-Dimethyl-T
7 2,α-DMT 2,α-Dimethyl-T
8 α,N-DMT α,N-Dimethyl-T
9 DPT N,N-Dipropyl-T
10 EiPT N-Ethyl-N-isopropyl-T
11 AET α-Ethyl-T
12 ETH-LAD 6,N,N-Triethyl-NL
13 Harmaline 3,4-Dihydro-7-methoxy-1-methyl-C
14 Harmine 7-Methyoxy-1-methyl-C
15 4-HO-DBT N,N-Dibutyl-4-hydroxy-T
16 4-HO-DET N,N-Diethyl-4-hydroxy-T
17 4-HO-DiPT N,N-Diisopropyl-4-hydroxy-T
18 4-HO-DMT N,N-Dimethyl-4-hydroxy-T
19 5-HO-DMT N,N-Dimethyl-5-hydroxy-T
20 4-HO-DPT N,N-Dipropyl-4-hydroxy-T
21 4-HO-MET N-Ethyl-4-hydroxy-N-methyl-T
22 4-HO-MiPT 4-Hydroxy-N-isopropyl-N-methyl-T
23 4-HO-MPT 4-Hydroxy-N-methyl-N-propyl-T
24 4-HO-pyr-T 4-Hydroxy-N,N-tetramethylene-T
25 Ibogaine A complexly substituted-T
26 LSD N,N-Diethyl-L
27 MBT N-Butyl-N-methyl-T
28 4,5-MDO-DiPT N,N-Diisopropyl-4,5-methylenedioxy-T
29 5,6-MDO-DiPT N,N-Diisopropyl-5,6-methylenedioxy-T
30 4,5-MDO-DMT N,N-Dimethyl-4,5-methylenedioxy-T
31 5,6-MDO-DMT N,N-Dimethyl-5,6-methylenedioxy-T
32 5,6-MDO-MiPT N-Isopropyl-N-methyl-5,6-methylenedioxy-T
33 2-Me-DET N,N-Diethyl-2-methyl-T
34 2-Me-DMT 2,N,N-Trimethyl-T
35 Melatonin N-Acetyl-5-methoxy-T
36 5-MeO-DET N,N-Diethyl-5-methoxy-T
37 5-MeO-DiPT N,N-Diisopropyl-5-methoxy-T
38 5-MeO-DMT 5-Methoxy-N,N-dimethyl-T
39 4-MeO-MiPT N-Isopropyl-4-methoxy-N-methyl-T
40 5-MeO-MiPT N-Isopropyl-5-methoxy-N-methyl-T
41 5,6-MeO-MiPT 5,6-Dimethoxy-N-isopropyl-N-methyl-T
42 5-MeO-NMT 5-Methoxy-N-methyl-T
43 5-MeO-pyr-T 5-Methoxy-N,N-tetramethylene-T
44 6-MeO-THH 6-Methoxy-1-methyl-1,2,3,4-tetrahydro-C
45 5-MeO-TMT 5-Methoxy-2,N,N-trimethyl-T
46 5-MeS-DMT N,N-Dimethyl-5-methylthio-T
47 MiPT N-Isopropyl-N-methyl-T
48 α-MT α-Methyl-T
49 NET N-Ethyl-T
50 NMT N-Methyl-T
51 PRO-LAD 6-Propyl-NL
52 pyr-T N,N-Tetramethylene-T
53 T Tryptamine
54 Tetrahydroharmine 7-Methoxy-1-methyl-1,2,3,4-tetrahydro-C
55 α,N,O-TMS α,N-Dimethyl-5-methoxy-T

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

TiHKAL

View on Grokipedia
from Grokipedia
is a 1997 book co-authored by medicinal chemist and psychopharmacologist , expanding on their prior work by cataloging synthesis procedures, dosage guidelines, and psychotropic effects for 55 derivatives, many synthesized by himself. The title serves as an acronym for "Tryptamines I Have Known and Loved," reflecting a structured of this class of serotonergic hallucinogens structurally related to endogenous neurotransmitters like serotonin and . Divided into a section chronicling the authors' personal and professional lives intertwined with psychedelic , and a technical compendium detailing chemical preparations alongside subjective human trials, the volume emphasizes empirical bioassay data over theoretical speculation. Shulgin's methodologies, rooted in systematic structural variation and self-administration, yielded novel insights into structure-activity relationships for compounds such as 4-HO-DMT () analogs and beta-carboline admixtures, influencing subsequent independent investigations into therapeutic applications for conditions like cluster headaches and . Despite its value as a primary reference for clandestine and academic chemists, the explicit inclusion of reproducible synthetic routes prompted regulatory scrutiny, with several documented subsequently classified as I substances by the U.S. to curb non-medical proliferation. The book's unfiltered documentation of experiential phenomenology, including visionary states and therapeutic , underscores Shulgin's for responsible amid prohibitive legal frameworks, prioritizing firsthand observation over institutionalized prohibitions.

Authors and Context

Alexander Shulgin's Career

earned a PhD in biochemistry from the , in 1955, following undergraduate studies in at the same institution completed in 1949. After a brief role as research director at , he joined in 1955 as a senior research chemist, where he focused on developing insecticides, notably inventing Zectran (4-dimethylamino-3,5-xylyl N-methylcarbamate), a patented in 1960. His work at Dow, spanning until 1967, emphasized synthetic applied to , yielding practical agricultural products amid post-World War II advancements in and technologies. Shulgin's pivot to psychopharmacology occurred during his Dow tenure, triggered by self-experimentation with in the early , which sparked systematic exploration of structure-activity relationships in derivatives. After departing Dow, he established a private laboratory on his , property, freelancing as a consultant while pursuing independent synthesis of psychoactive agents. In the late , he secured a DEA-issued license permitting the synthesis, possession, and personal testing of Schedule I controlled substances, a rare exemption grounded in his prior consulting role with the agency on clandestine laboratory identification. This enabled unrestricted research outside institutional constraints, culminating in the creation of approximately 200 novel psychoactive compounds by the 1990s, including the resynthesis and initial of (3,4-methylenedioxymethamphetamine) around 1970, which he characterized for its empathogenic properties before sharing samples with psychotherapists in 1977. Shulgin's research methodology prioritized direct human bioassays over preclinical animal models, reflecting the limitations of extrapolating subjective cognitive and perceptual effects from non-human subjects. He administered compounds to himself in progressively increasing doses to establish thresholds for physiological and psychological responses, followed by controlled sessions with a small cadre of trusted volunteers, meticulously recording onset, duration, qualitative phenomenology, and safety profiles in laboratory notebooks. This iterative, first-person empirical process generated precise dosage-effect data—such as effective ranges in milligrams and variability by set and setting—contrasting sharply with resource-intensive, protocol-bound institutional trials that often prioritize safety over exploratory breadth. By the mid-1990s, this approach had yielded foundational insights into psychedelic pharmacodynamics, informing the systematic documentation in PiHKAL (1991) and setting the stage for TiHKAL's focus on tryptamines.

Ann Shulgin's Contributions

, a self-trained Jungian therapist without formal credentials but with extensive practical , collaborated with her husband from the early 1970s onward, incorporating psychedelic substances into exploratory sessions that blended with psychological observation. Her approach prioritized the subjective human response, using lay techniques to facilitate group and individual encounters with psychoactive compounds, including tryptamines, to uncover emotional and perceptual patterns. This integration marked a shift from purely pharmacological inquiry to experiential analysis, where she documented how molecular variations influenced introspective states and interpersonal dynamics. As co-author of TiHKAL, published in 1997, Ann provided the "Extensions and Commentary" for each profile, compiling narrative reports from personal trials and facilitated group sessions that detailed qualitative effects such as visual distortions, enhancement, and therapeutic breakthroughs in relational processing. These sections emphasize causal linkages between chemical substitutions—often devised by —and observed psychological outcomes, including dosage thresholds for onset (typically 1-20 mg for active compounds) and duration (4-12 hours), while stressing preparatory mindset and environmental factors to mitigate risks. Her contributions grounded the book's chemical data in lived phenomenology, attributing insights to empirical self-experimentation rather than abstract theory. Ann's editing role extended to refining entries for therapeutic , incorporating anonymized accounts from diverse participants to illustrate variability in responses across demographics and contexts, thus bridging synthetic precision with holistic integration strategies. This dynamic ensured TiHKAL served not only as a reference for synthesis but as a cautionary guide on responsible exploration, highlighting potential for psychological healing while acknowledging variability in individual sensitivity. Her perspective, informed by decades of non-clinical practice, underscored the tryptamines' utility in addressing trauma and without endorsing recreational use.

Relation to PiHKAL

TiHKAL functions as the direct sequel to : A Chemical Love Story, which and published in 1991 through their imprint, Transform Press. Whereas catalogs the synthesis, dosage guidelines, and subjective effects of over 170 compounds—many synthesized or characterized by Shulgin himself— applies an analogous structure to 55 tryptamines, extending the exploratory methodology to a distinct chemical family. This continuity in format underscores the Shulgins' systematic approach to documenting psychoactive substances, blending technical chemical protocols with autobiographical vignettes and firsthand qualitative reports from controlled administrations. The pivot to tryptamines in TiHKAL reflects their biochemical affinity to , a key , positioning them as natural extensions of psychedelic research beyond the class, which aligns more closely with pathways. Tryptamines encompass endogenous psychedelics like N,N-dimethyltryptamine (DMT), found in mammalian tissues and plants, offering untapped potential for pharmacological insight compared to , whose profiles Shulgin had already extensively mapped in . This shift enabled deeper inquiry into serotonin-modulating effects, including variations in substitution at the ring, which influence potency and duration without the prior saturation of variants. Both volumes share a foundational philosophy critiquing the U.S. Drug Enforcement Administration's (DEA) analog scheduling under the Controlled Substances Act, which the Shulgins portrayed as arbitrary and obstructive to scientific inquiry. PiHKAL's publication prompted DEA scrutiny and the revocation of Shulgin's Schedule I research license in 1994, events detailed in TiHKAL's opening narrative, where the authors reiterate calls for evidence-based regulation over blanket prohibitions that hinder empirical evaluation of compounds' risks and benefits. This shared advocacy frames TiHKAL not merely as a chemical compendium but as a continuation of PiHKAL's challenge to institutionalized barriers in psychopharmacology.

Publication History

Development and Writing (1990s)

Following the 1991 publication of PiHKAL, Alexander Shulgin redirected his psychopharmacological research toward tryptamines, synthesizing structural analogs in his home laboratory at Willow Dale Farm in Lafayette, California, to explore variations in potency and qualitative effects. This phase built on prior methodologies, incorporating multi-step organic reactions to modify the tryptamine backbone while prioritizing compounds amenable to small-scale production. From the early 1990s through 1996, Shulgin and his wife Ann conducted iterative self-experiments, administering incrementally increasing doses to over 50 derivatives to establish empirical thresholds for psychoactivity, duration, and subjective phenomenology, with data recorded in real-time journals for later compilation. This process occurred amid escalating regulatory pressure, including a 1994 DEA search of the laboratory that uncovered undeclared samples, leading to a $25,000 fine and revocation of Shulgin's Schedule I license, though no criminal charges ensued and unscheduled work persisted under stricter documentation. Synthesis protocols emphasized reproducibility, addressing challenges such as side in reductive aminations and purification of thermally unstable intermediates, with botanical precedents like DMT from sources informing for enhanced stability and yield in home-lab settings. By mid-decade, this groundwork yielded detailed accounts integrated into the , finalized for publication in 1997.

Release in 1997

TiHKAL: The Continuation was published in by Transform Press, the independent publishing house founded by Alexander and in 1991. The volume spans 804 pages and includes comprehensive indices for , dosage recommendations typically ranging from 5 to 50 mg, and effect durations averaging 4 to 12 hours for the profiled tryptamines. The release occurred three years after the U.S. (DEA) raided the Shulgins' home and laboratory in 1994, revoking Alexander Shulgin's Schedule I research license for alleged violations related to unapproved sharing of samples and imposing a fine of approximately $25,000 to $40,000. This event heightened tensions with federal authorities, positioning the book's open documentation of synthesis protocols and subjective experiences as a deliberate counterpoint to perceived regulatory secrecy and restrictions on psychoactive research. Initial distribution emphasized direct sales from Transform Press and select independent channels, priced at $24.50 for the edition, to circumvent potential mainstream suppression amid ongoing scrutiny from drug enforcement agencies. The work garnered immediate interest within scientific and psychonaut communities for its unprecedented detail on 55 compounds, though broader public reception was constrained by the niche subject matter and legal sensitivities.

Distribution and Accessibility

TiHKAL disseminated primarily through informal networks within psychedelic and enthusiast communities following its 1997 , relying on word-of-mouth recommendations and direct sales from Transform Press rather than broad commercial outlets. This underground propagation evaded potential institutional censorship, as the book's explicit synthesis instructions for controlled substances attracted scrutiny from regulatory bodies like the DEA, yet its as published allowed circulation among self-experimenters and chemists. The original edition's relatively high production costs, driven by and inclusion of complex chemical diagrams, restricted initial access to those willing to pay premium prices, often exceeding $40 per copy through limited print runs. Accessibility expanded significantly with the proliferation of unauthorized PDF scans across online archives and file-sharing platforms, which bypassed copyright restrictions and enabled widespread digital replication despite legal challenges from the authors' estate. Complementing this, .org hosts a permitted version, allowing non-commercial distribution of the catalog sections while reserving the autobiographical content, thereby providing a semi-official digital gateway for global users. International reach grew via translations into Spanish and German, with additional languages in development, facilitating adoption in non-English-speaking research circles. These mechanisms collectively empowered independent syntheses, as verifiable protocols for compounds like 4-HO-DMT and supported cautious replication studies by practitioners prioritizing over institutional gatekeeping.

Book Structure and Methodology

Autobiographical Framework

The autobiographical framework of TiHKAL forms the foundational narrative of the book's first eight chapters, continuing the fictionalized personal chronicle begun in PiHKAL. Presented through alternating first-person accounts from the pseudonymous "Shura" (Alexander Shulgin) and "Alice" (Ann Shulgin), these sections depict chronological vignettes of their lives starting from the mid-1980s, blending intimate relational developments with the intellectual and experimental pursuit of psychoactive substances. This structure provides causal context for their shift from phenethylamine research—exemplified by MDMA, which faced emergency scheduling by the DEA on July 1, 1985, limiting its therapeutic use—to systematic exploration of tryptamines as alternatives for psychological insight and relational enhancement. Central to these narratives is the emphasis on interpersonal dynamics during substance testing, drawn from the Shulgins' direct experiences. , leveraging her background in , highlights how shared dosing in committed relationships or small groups often yielded synergies—such as amplified and mutual insight—not evident in solo administrations, attributing this to the relational amplification of neurochemical effects rather than isolated pharmacological action. complements this with accounts of collaborative synthesis and initial trials at their home laboratory, underscoring how personal trust facilitated precise of variables like dosage timing and environmental set, yielding unattainable through detached protocols. These elements frame their work as an extension of therapeutic practice, post-MDMA restrictions, where tryptamines served to map emotional and cognitive causal pathways . The framework also conveys a meta-critique of institutional scientific paradigms, advocating empirical self-experimentation as a principled alternative to precautionary animal modeling or regulatory stasis. The Shulgins portray mainstream research caution—exacerbated by events like the ban—as obscuring direct on human phenomenology, favoring instead iterative, first-person validation to delineate effect profiles without preconceived moral filters. This approach, rooted in their observed outcomes, positions the inquiries as a logical progression from prior limitations, prioritizing verifiable experiential data over abstracted safety thresholds.

Chemical Synthesis Protocols

The synthesis protocols detailed in TiHKAL emphasize practical, lab-scale methods for tryptamine derivatives, typically starting from commercially available precursors like or base, with step-by-step instructions including reagent quantities, reaction conditions, and analytical verification via melting points or . These procedures prioritize reproducibility, often achieving yields of 50-80% through optimized conditions such as controlled temperatures and inert atmospheres to minimize side reactions like over-alkylation. A primary route involves , where is first converted to 3-(2-nitrovinyl) via Henry reaction with and , followed by reduction to using lithium aluminum hydride (LAH) in ether, with subsequent N- using alkyl halides or reductive methods; purification entails acidification to the salt and recrystallization from , ensuring >95% purity as confirmed by sharp melting points. represents another common pathway for N,N-dialkylated variants, reacting with aldehydes (e.g., for methylation) and sodium triacetoxyborohydride or cyanoborohydride in methanolic solution at pH 6-7, stirred for 24-48 hours, followed by extraction with and ; yields here range from 60-75%, with impurities like unreacted removed via acid-base . For substituted tryptamines, protocols adapt these routes to accommodate ring modifications, such as 5-methoxy derivatives via starting from 5-methoxy and proceeding through analogous , or 4-hydroxy analogs requiring strategies (e.g., ) to prevent oxidative degradation during reduction steps, with deprotection via mild ; these variations underscore empirical observations of how substituents influence reactivity, such as methoxy groups enhancing nucleophilicity in indole C-3 position. Safety considerations in the protocols highlight the use of fume hoods for volatile amines, gloves for irritants like LAH, and neutralization of cyanide-containing reducing agents, while noting the flammability of solvents like THF and the need for anhydrous conditions to avoid explosive byproducts. These methods draw from established routes like Speeter-Anthony for dialkylation but are refined through iterative experimentation for higher selectivity.

Dosage, Duration, and Qualitative Reports

In TiHKAL, dosage recommendations for tryptamines are expressed as ranges in milligrams for , with threshold effects often emerging at 10-20 mg for many synthetic derivatives, such as or , while full psychoactive doses scale to 20-50 mg or higher depending on potency and individual variability. These estimates derive from self-experiments by and associates, prioritizing incremental titration to identify minimally active levels before escalating. Duration profiles follow a consistent pattern across entries: onset typically 30-60 minutes post-ingestion, peaking at 2-4 hours, with total primary effects lasting 4-8 hours and residual aftereffects extending to 12 hours or more. Shulgin correlates these timelines to physicochemical properties, noting that increased and molecular weight generally prolong onset and extend duration by enhancing blood-brain barrier penetration and metabolic persistence, as observed in comparisons between homologs like DMT (shorter, ~1-2 hours smoked) and longer-acting analogs like 4-HO-DPT. Qualitative reports structure observations using the , a semi-quantitative metric where +/- indicates threshold awareness, + mild sensory enhancement without impairment, ++ moderate visuals and emotional shifts (e.g., colored patterns or introspective clarity), +++ strong dissociation from baseline reality, and ++++ total transcendence with ego dissolution. These accounts detail perceptual alterations—such as geometric hallucinations and —and cognitive effects like or insight generation, attributed mechanistically to at serotonin 5-HT2A receptors, which disrupt activity and amplify cortical excitability. Common adverse effects include and , especially during onset, linked to peripheral serotonin receptor activation in the gut; reports stress dose-dependent risks without endorsing therapeutic claims. This empirical format favors verifiable timelines and intensities over interpretive narrative, enabling cross-compound comparisons while acknowledging inter-subject variability from factors like set, setting, and metabolism.

Catalog of Tryptamines

Overview of Listed Compounds

TiHKAL catalogs 55 tryptamine compounds, exploring derivatives of the core structure through systematic substitutions primarily at the 3-indole position (e.g., hydroxy or methoxy groups), the side chain (e.g., N,N-dialkyl variations), and occasionally alpha-methyl additions or ring modifications like . These entries encompass both established psychedelics and novel analogs synthesized by , with core examples including DMT (#3), (#38), and (#43, as 4-HO-DMT), as well as innovative variants such as (#48) and multiple DET derivatives like 4-HO-DET (#28). The catalog methodically progresses from unsubstituted (#1) to increasingly complex forms, emphasizing reproducible synthesis and data over theoretical predictions. Compounds are implicitly grouped by substitution patterns, revealing clusters such as the 4-hydroxy series (10 entries, often mimicking 's profile), the 5-methoxy series (12 entries, noted for intensified effects), N-alkyl variations (e.g., dimethyl, diethyl, dipropyl), and five methylenedioxy-substituted tryptamines probing fused-ring enhancements. Activity baselines differentiate short-duration smoked routes—predominant for DMT and , yielding 10-30 minute experiences—from oral actives like or , which extend to 4-6 hours but may demand higher thresholds or adjuncts like inhibitors for efficacy. Inactive analogs, including certain bulky N-substitutions or atypical ring alterations, demonstrate SAR boundaries, where deviations from optimal electron distribution or abolish psychoactivity despite structural proximity to actives. Shulgin's self-experimentation yields an empirical potency hierarchy, with 5-methoxy variants often surpassing 4-hydroxy counterparts in threshold sensitivity (e.g., 5-MeO-DMT active at 2-5 mg smoked versus psilocin's 4-8 mg oral), while underscoring dose-response linearity absent in untested hype surrounding rare or impure variants. This approach privileges observed thresholds and durations over anecdotal extrapolation, highlighting how SAR constraints—such as steric hindrance in N-ethyl/methyl hybrids—limit generalizations to unassayed compounds.

Notable Entries and Their Profiles

DMT (N,N-dimethyltryptamine, C₁₂H₁₆N₂), an endogenous compound naturally occurring in trace amounts in the and various , is profiled in TiHKAL as producing profound, short-acting psychedelic effects when administered via or injection. Breakthrough doses of 30-50 mg smoked yield rapid onset visuals including intricate geometric patterns and reports of encounters with autonomous entities, often described as machine elves or other intelligences, alongside ego dissolution and cosmic expansion. Higher doses up to 100 mg intensify these to overwhelming levels, with duration typically under 15 minutes for the peak experience. 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine, C₁₃H₁₈N₂O) elicits exceptionally intense, non-ordinary states emphasizing non-visual over entity contact, with smoked doses of 5-15 mg sufficient for threshold to strong effects characterized by blinding white light, unconditional unity, and dissolution into pure consciousness. Its duration is brief, often 10-20 minutes, distinguishing it from longer-acting tryptamines, and reports highlight terror or ecstasy without retained intellectual narrative, underscoring its potency at low milligram levels.
CompoundFormulaTypical Dosage (Oral/Smoked)DurationCore Effects
DMTC₁₂H₁₆N₂Inactive orally; 30-100 mg smoked<1 hourEntity encounters, visuals, endogenous trace presence
5-MeO-DMTC₁₃H₁₈N₂OInactive orally; 6-20 mg smoked1-2 hoursNon-visual mysticism, unity dissolution, intense overload
4-HO-DIPTC₁₆H₂₄N₂O15-20 mg oral2-3 hoursIntrospective stimulation, mild tremors, limited visuals with potential auditory enhancement selectivity
4-HO-DIPT (4-hydroxy-N,N-diisopropyltryptamine, C₁₆H₂₄N₂O), a synthetic, demonstrates sensory selectivity in reports, with oral doses of 15-20 mg producing stimulation, muscle relaxation, and emphasized auditory distortions akin to pitch-shifting without dominant visuals. Its profile includes leg tremors and elation peaking within 20-50 minutes, fading by 2-3 hours, positioning it as a tool for exploring modality-specific hallucinations distinct from classical serotonergic patterns.

Scientific Contributions

Novel Syntheses and Pharmacology

In TiHKAL, detailed the synthesis of 55 analogs, many of which represented first-time preparations of substituted variants such as 4-hydroxy and 5-methoxy derivatives, employing standard organic techniques including modifications and of indole-3-propionaldehyde precursors. These protocols advanced chemistry by providing reproducible laboratory-scale methods for compounds previously inaccessible or undescribed, emphasizing the role of substituent position in yield and purity. A key innovation involved alpha-alkylated tryptamines, such as alpha-methyltryptamine (αMT), where the addition of a at the alpha-carbon of the extended pharmacological duration to 18-24 hours, compared to 4-6 hours for unsubstituted analogs like DMT, attributed to resistance against degradation. Shulgin empirically validated this through threshold dosing, observing prolonged stimulant and hallucinogenic effects that aligned with serotonin mimetic models, where the ethylamine chain substitution modulated onset and persistence without proportionally altering potency. Pharmacologically, TiHKAL contributed structure-activity relationship (SAR) insights linking 4-position hydroxylation to enhanced affinity for serotonin-like binding sites, prefiguring confirmatory studies on agonism as the primary mediator of hallucinogenic effects in tryptamines. Shulgin's variants demonstrated that ring substitutions (e.g., at positions 4, 5, or 6) influenced selectivity, with data suggesting weaker interactions at non-psychedelic serotonin subtypes, though these hypotheses derived from qualitative correlations rather than direct radioligand assays. These advancements were limited by the absence of preclinical , with safety inferences drawn solely from human threshold doses and absence of acute adverse effects in self-trials, potentially overlooking cumulative or idiosyncratic toxicities unapparent in small cohorts. Subsequent research has validated core SAR patterns but highlighted needs for binding and animal models to quantify risks like cardiovascular strain from prolonged exposure.

Empirical Self-Experimentation Approach

and employed a systematic protocol of self-experimentation in TiHKAL, synthesizing analogs and administering them incrementally to map dose-response relationships through direct subjective observation. Starting with low, sub-threshold doses—often in the range of 1-5 mg for novel compounds—they escalated quantities in subsequent sessions until threshold effects emerged, minimizing variables by conducting tests in familiar, controlled settings with minimal environmental interference. This escalation allowed precise delineation of qualitative shifts, such as transitions from mild perceptual alterations to intense visuals or emotional insights, recorded via Shulgin's standardized rating scale ranging from "plus one" (threshold) to "plus four" (complete disruption of ordinary reality). The approach embodied causal realism by linking specific dosages and structural modifications directly to experiential outcomes, bypassing the averaging effects of large-scale trials in favor of granular, individual-level data. Unlike randomized controlled trials, which demand institutional approvals and extended timelines often prohibitive for Schedule I substances, self-experimentation enabled rapid iteration—compounds could be assessed within weeks rather than years—facilitating hypothesis-testing on human phenomenology where animal models prove inadequate due to psychedelics' negligible impact on non-human subjects. This yielded verifiable patterns, such as consistent geometric visuals tied to 4-position substitutions on the indole ring, observable across multiple sessions and volunteers. Key advantages lay in its efficiency for exploratory pharmacology: Shulgin tested over 200 compounds personally, generating foundational data on therapeutic potentials like empathy enhancement, which informed subsequent clinical validations without initial reliance on blinded protocols. Drawbacks included inherent subjectivity and selection bias, as participants comprised a small, self-selecting cohort of psychologically robust individuals predisposed to introspection, potentially skewing reports toward positive or novel effects while underrepresenting adverse reactions in broader populations. Lacking placebo controls or double-blinding, the method risked confirmation bias, though cross-validation via repeated trials and structural analogies mitigated this to some extent. Notwithstanding limitations, the methodology's emphasis on replicable dose-effect correlations provided empirical rigor, contrasting institutional stalled by ; for example, escalating doses reliably predicted potency hierarchies that aligned with later binding affinity studies on serotonin receptors. This direct-observation paradigm underscored the value of n-of-1 designs for subjective domains, where aggregate statistics may obscure causal nuances essential for causal realism in consciousness .

Interactions with DEA Scheduling

maintained a DEA Schedule I from the early 1970s until 1994, permitting the synthesis, possession, and analytical study of controlled s without immediate criminal liability, which facilitated the empirical underlying TiHKAL. This exemption, rare for non-pharmaceutical entities post-1970 , enabled Shulgin to explore over 50 novel structures documented in the book, many of which demonstrated psychoactive potency comparable to scheduled substances like DMT yet remained unscheduled at the time of publication. In September 1994, following the 1991 release of —which detailed syntheses later targeted under the 1986 —DEA agents raided Shulgin's laboratory, citing violations such as possession of unlabeled samples sent for analysis and minor record-keeping discrepancies. The agency imposed a $25,000 fine and revoked his Schedule I license, effectively halting federally sanctioned work on controlled substances and prompting Shulgin to surrender the authorization under threat of further enforcement. TiHKAL, published in 1997, reflects this revocation through its preface and appendices, where Shulgin critiques the DEA's expansive interpretation of the Analogue Act to preemptively classify structural variants without or data, as seen in cases like alpha-ethyltryptamine (α-ET), initially deemed non-analogous by DEA chemists before retroactive scrutiny. The book posits that numerous unscheduled tryptamines (e.g., , ) exhibit threshold effects at 5-20 mg doses—rivalling scheduled psychedelics—yet lack of inherent danger justifying , thereby questioning scheduling criteria centered on unsubstantiated potential rather than verifiable metrics. This stance underscores Shulgin's view of regulatory overreach, informed by his prior advisory role to DEA on clandestine syntheses, without conceding to institutional narratives of uniform risk.

Challenges to Prohibitionist Frameworks

TiHKAL implicitly undermines prohibitionist paradigms by cataloging tryptamines' pharmacological profiles, which reveal low profiles incompatible with blanket Schedule I classifications emphasizing high abuse potential and negligible medical value. Shulgin reports minimal adverse physical effects across dozens of compounds at exploratory doses, such as 100 mg smoked DPT producing effects "more benign than mushrooms" without pathological sequelae, and 250 mg intravenous eliciting transient LSD-like states but rapid recovery due to metabolic clearance. These observations align with broader toxicological data on serotonergic hallucinogens, where psilocybin's LD50 exceeds 280 mg/kg in —orders of magnitude above human therapeutic doses—contrasting with ethanol's narrower safety margin and established lethality at recreational levels. Shulgin's documentation of therapeutic signals, including DPT-facilitated emotional recall in and alpha-ethyltryptamine's utility in opiate withdrawal, further contests the zero-tolerance framework by highlighting potential benefits suppressed under . The text critiques moral panics fueling prohibition by contextualizing tryptamines within millennia-old shamanic traditions, such as and in preparations or in snuffs and alvarius venom, where ritualistic use fostered cultural continuity rather than collapse. Shulgin notes these practices' endurance across indigenous societies without the addictive epidemics or overdose crises characterizing modern prohibitions, attributing policy failures to regulatory overreach rather than inherent substance dangers—evident in the tryptophan ban, which curtailed access to a low-risk precursor amid unsubstantiated toxicity claims post-eosinophilia-myalgia syndrome. This historical lens exposes prohibition's ahistorical bias, prioritizing punitive control over evidence of contextual safety in non-coercive settings. Shulgin advances via first-hand empirical , positing that transparent synthesis protocols and dosage reports empower informed personal use over clandestine risks amplified by bans. He challenges the Controlled Substances Analogue Act's vagueness, which could hypothetically deem alcohol or "substantially similar" to scheduled substances, inflating costs (e.g., alpha-ethyltryptamine from $60.90 to $424,000 per 100g post-scheduling) and eroding without commensurate public health gains. By framing access as a constitutional —exemplified by the Temple of the True Inner Light's exempted DPT use under religious freedoms—TiHKAL substantiates reform rooted in individual and verifiable low-harm empirics, rather than fear-driven restrictions.

Controversies and Criticisms

Promotion of Underground Synthesis

Critics contend that TiHKAL facilitates illicit tryptamine production by furnishing detailed, replicable synthesis protocols that specify reagents, reaction conditions, and gram-scale yields, such as the 4.78 g starting material used in one indole-based procedure yielding defined products. These instructions, critics argue, democratize access to controlled substances for non-experts lacking institutional oversight or quality controls, potentially exacerbating underground manufacturing. Law enforcement analyses describe TiHKAL alongside PiHKAL as practical manuals for synthetic drug chemistry, enabling clandestine operators to bridge gaps in prior literature. Defenders counter that the book's disclosures merely compile and clarify fragmented historical syntheses, not invent novel illicit methods, while explicitly cautioning against the perils of impure intermediates or side products, which Shulgin stressed could introduce toxic contaminants absent in controlled settings. Shulgin's protocols underscore the necessity of rigorous purification to avoid undefined impurities, positioning the text as a tool for informed rather than reckless enablement. This perspective holds that withholding such details perpetuates reliance on unverified street sources, inherently riskier due to variability. Post-1997, TiHKAL's release correlated with documented clandestine lab discoveries involving attempts, mirroring PiHKAL's prior associations with seized operations worldwide, where texts served as operational guides amid enforcement raids. reports on synthetic drug labs highlight how such publications inform production trends, though attribution to TiHKAL specifically remains inferential amid broader underground adaptations. No peer-reviewed studies quantify direct causation, but agency observations link the book's accessibility to heightened synthesis pursuits lacking pharmaceutical safeguards.

Health and Safety Risks from Self-Reports

Self-reports in TiHKAL document instances of acute psychological distress, including intense anxiety, , and "bad trips" characterized by overwhelming fear or confusion, particularly at higher doses of compounds like 4-HO-DET and , where participants described experiences as "uncomfortable" or "disturbing" without resolution in the immediate session. These accounts highlight risks of transient but severe emotional turmoil, with post-experience depression reported in up to 15% of cases for similar tryptamines, though long-term psychological follow-up was absent in the book's . Physical adverse effects noted in the reports include , , muscle tension, and , common across multiple entries such as with and 5-methoxy variants, potentially exacerbating or discomfort during intoxication. Cardiovascular strain appears elevated in 5-MeO-substituted tryptamines, with self-experimenters observing transient increases in and , aligning with broader pharmacological data on these agents' sympathomimetic properties. Potential for exists due to the compounds' at 5-HT receptors and inhibition of serotonin reuptake, especially in combinations or overdoses, though TiHKAL reports did not explicitly document full syndromes. Hallucinogen persisting perception disorder (HPPD) risks, involving ongoing visual disturbances like trails or geometric patterns, remain unaddressed in TiHKAL's short-term self-reports, as no longitudinal tracking was conducted; general evidence links such persistent effects to repeated high-dose use, underscoring a gap in the data for novel tryptamines. The self-reports' limitations for risk assessment stem from their anecdotal nature: small, non-random samples of experienced , absence of controlled cohorts, and likely underreporting of negatives due to among enthusiasts inclined toward positive outcomes, rendering the data insufficient for population-level safety inferences without corroborative clinical studies.

Ideological Debates on Drug Freedom vs. Public Health

Shulgin's work in TiHKAL reflects a libertarian emphasizing individual in chemical exploration, positing that responsible adults possess the inherent right to investigate consciousness-altering substances without state interference, as distorts and fosters black-market dangers greater than the compounds' inherent profiles. He argued that tryptamines, with their low physiological toxicity and absence of compulsive use patterns, mirror legal substances like alcohol, where societal prevails despite documented harms, and empirical self-reports in the book demonstrate potential for profound psychological insights outweighing sporadic adverse reactions in screened users. Advocates extending this ethos cite preclinical and indicating negligible liability for classic tryptamines, such as psilocybin's failure to meet high-abuse criteria under the U.S. Controlled Substances Act's eight factors, including rapid tolerance onset and lack of withdrawal syndromes. Opponents from perspectives contend that TiHKAL's detailed syntheses enable unregulated dissemination, amplifying risks of adulterated production and unsupervised dosing, particularly for novices lacking Shulgin's pharmacological expertise, potentially serving as gateways to broader polysubstance experimentation among without medical gatekeeping. underscores tryptamines' low but highlights substantial inter-individual variability in outcomes, with controlled studies showing therapeutic benefits for depression in select cohorts yet elevated psychosis exacerbation in those with latent vulnerabilities, as evidenced by post-administration monitoring revealing transient but severe in 5-10% of healthy volunteers. Critics, including regulatory bodies, argue this variability necessitates supervised frameworks to mitigate population-level harms, noting that self-experimentation reports overlook long-term sequelae like reported in 4.2% of recreational users per survey data. Reconciling viewpoints, data affirm tryptamines' favorable profile relative to opioids or stimulants—evidenced by overdose rarity and absence of lethal respiratory depression—but underscore causal realism in harms arising from contextual factors like set, setting, and polydrug interactions rather than inherent addictiveness, prompting debates on whether freedom-oriented policies could incorporate education to address without blanket . Proponents of Shulgin's framework advocate empirical validation through pilots, akin to Oregon's 2020 Measure 109, which yielded no surge in adverse events per initial monitoring, while skeptics prioritize precautionary principles given incomplete longitudinal data on novel analogs detailed in TiHKAL.

Impact and Legacy

Influence on Psychedelic Research

TiHKAL provided detailed syntheses, structure-activity relationships (SAR), and phenomenological reports on over 50 , serving as a foundational reference for post-1997 pharmacological studies. Researchers have cited the book's data on psychoactivity and binding affinities to model hallucinogenic potential, as in approaches to predict molecular effects based on Shulgin's empirical observations. Similarly, investigations into interactions with transporters drew from TiHKAL's characterizations of compounds like 5-methoxy-DMT to inform receptor binding assays conducted in the . The book's synthetic protocols enabled the development of novel analogs for therapeutic applications, with multiple patents explicitly adapting Shulgin's methods for scalable production. For instance, European Patent EP3844147B1 (granted 2023) describes synthesis "adapted from Alexander Shulgin's pioneering publication TiHKAL," facilitating formulations aimed at non-hallucinogenic psychedelics. U.S. 20210395201 (filed 2021) likewise references TiHKAL for N,N-dimethyl-type compounds, underscoring its role in bridging to patented innovations in SAR-driven . By documenting systematic self-experimentation and pharmacological insights amid regulatory suppression, TiHKAL contributed to destigmatizing research, aligning with the resurgence of FDA-approved trials in the and 2010s. Its emphasis on dose-response data paralleled the rigor in studies like those yielding designations for in (e.g., FDA designation to Pathways in 2018). Shulgin's work, as noted in historical analyses, helped legitimize psychedelics as subjects for clinical inquiry by demonstrating reproducible effects, influencing protocols in institutions previously hesitant due to Schedule I classifications.

Cultural and Therapeutic Developments Post-1997

The detailed phenomenological reports in TiHKAL provided early empirical insights into dose-response relationships and subjective effects, influencing subsequent protocols where sub-perceptual doses of compounds like are administered for potential enhancements in mood, creativity, and focus. These self-experiments documented threshold levels and minimal physiological disruption for many analogs, informing non-clinical practices that gained traction in the amid growing interest in sub-hallucinogenic use for mental well-being. Post-2018 clinical investigations into DMT and for PTSD and related disorders have corroborated select TiHKAL-described effects, such as heightened emotional accessibility and neuroplasticity-linked , underpinning protocols in psychedelic-assisted trials. For instance, DMT studies from 2021 onward have explored rapid-onset therapeutic windows, aligning with Shulgin's reports of short-duration, profound alterations without sustained toxicity. These developments reflect a broader , where historical self-report data bridges to controlled settings, emphasizing set, setting, and integration to mitigate risks observed in uncontrolled use. TiHKAL's advocacy for open synthesis and experimentation bolstered underground psychedelic networks, contributing to cultural phenomena like transformational festivals (e.g., post-2000 events emphasizing entheogenic exploration) where use aligns with themes of and communal . This has faced critique for potentially romanticizing psychological vulnerabilities, especially amid the opioid epidemic's focus on acute physical harms; however, tryptamines exhibit low abuse liability and negligible overdose rates in aggregated reports, contrasting sharply with ' 50,000+ annual U.S. fatalities. In the 2020s, such low-harm evidence from extensive and documentation supported policy shifts, including Oregon's Measure 109 (passed November 2020), which legalized supervised services and cited psychedelics' favorable safety profiles relative to scheduled substances. This measure, implemented from 2023, enables licensed administration for adults 21+, drawing on decades of data indicating minimal physiological dependence for class members explored in TiHKAL. Subsequent trials under these frameworks continue validating therapeutic outcomes, with effect sizes for symptom reduction in depression pilots exceeding those of traditional antidepressants.

References

  1. https://erowid.org/library/books/tihkal.shtml
  2. https://books.google.com/books/about/Tihkal.html?id=jl_ik66IumUC
  3. https://www.maps.org/product/tihkal-the-continuation/
  4. https://blossomanalysis.com/books/tihkal/
  5. https://citylights.com/general/tihkal-the-continuation/
  6. https://www.barnesandnoble.com/w/tihkal-alexander-shulgin/1111674721
  7. https://cen.acs.org/articles/92/i33/Alexander-T-Sasha-Shulgin.html
  8. https://www.theguardian.com/science/2014/jun/03/alexander-shulgin
  9. https://www.chemistryworld.com/opinion/a-mind-blowing-legacy/7457.article
  10. https://shulginresearch.net/about/sasha_shulgin/
  11. https://www.nytimes.com/2005/01/30/magazine/dr-ecstasy.html
  12. https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.2010.02948.x
  13. https://www.scientificamerican.com/article/self-experimenter-chemist-explores-new-psychedelics/
  14. https://maps.org/news/media/chemist-alexander-shulgin-popularizer-of-the-drug-ecstasy-dies-at-88/
  15. https://shulginfoundation.org/about-the-shulgins/
  16. https://www.theguardian.com/society/2022/aug/05/ann-shulgin-obituary
  17. https://www.chacruna.net/ann-shulgin-obituary/
  18. https://www.economist.com/obituary/2022/08/11/ann-shulgin-pioneered-the-use-of-psychedelics-in-therapy
  19. https://www.latimes.com/obituaries/story/2022-07-13/ann-shulgin-pioneer-of-using-ecstasy-and-other-psychedelic-drugs-in-therapy-dies
  20. https://synergeticpress.com/blog/consciousness-and-psychedelics/remembering-ann-shulgin-the-matriarch-of-the-psychedelic-movement/
  21. https://transformpress.com/pihkal-a-chemical-love-story/
  22. https://www.ucl.ac.uk/~ucbtdag/bioethics/writings/shulgin.html
  23. https://www.academia.edu/44248661/Tihkal_Alexander_Shulgin
  24. https://the-eye.eu/public/Books/World%2520Tracker%2520Library/worldtracker.org/media/library/Law%2520Enforcement/Drugs/TiHKAL%2520The%2520Continuation%2520-%2520Shulgin.pdf
  25. https://www.wired.com/2002/09/professorx/
  26. https://maps.org/2014/02/28/the-second-psychedelic-revolution-part-two-alexander-sasha-shulgin-the/
  27. https://www.scientificamerican.com/blog/cross-check/talking-death-with-the-late-psychedelic-chemist-sasha-shulgin/
  28. https://www.vice.com/en/article/goodbye-alexander-shulgin/
  29. https://transformpress.com/tihkal-tryptamines-i-have-known-and-loved-the-continuation/
  30. https://www.goodreads.com/book/show/271921.Tihkal
  31. https://archive.org/details/tihkalcontinuati0000shul
  32. https://erowid.org/library/books_online/tihkal/tihkal.shtml
  33. https://transformpress.com/tihkal-tryptamines-i-have-known-and-loved-digital-book/
  34. https://www.science.org/content/blog-post/alex-shulgin-1925-2014
  35. https://chemistry.mdma.ch/hiveboard/picproxie_docs/000532880-Alexander_Shulgin_and_Ann_Shulgin_-_TiHKAL.pdf
  36. https://www.researchgate.net/publication/8009784_Analytical_chemistry_of_synthetic_routes_to_psychoactive_tryptamines_-_Part_II_Characterisation_of_the_Speeter_and_Anthony_synthetic_route_to_NN-dialkylated_tryptamines_using_GC-EI-ITMS_ESI-TQ-MS-MS_a
  37. https://www.researchgate.net/publication/45279601_Characterization_of_the_synthesis_of_NN-dimethyltryptamine_by_reductive_amination_using_gas_chromatography_ion_trap_mass_spectrometry
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC4194234/
  39. https://shulginresearch.net/wp-content/uploads/2021/07/Synthesis-and-characterization-of-5-methoxy-2-methyl-NN-dialkylated-tryptamines.-Brandt.-Drug-Test.-Anal.-4-24-32-2012.pdf
  40. https://www.sciencedirect.com/science/article/abs/pii/S0731708504004030
  41. https://www.erowid.org/library/books_online/tihkal/tihkal.shtml
  42. https://www.erowid.org/library/books_online/tihkal/shulgin_rating_scale.shtml
  43. https://www.erowid.org/library/books_online/tihkal/tihkal13.shtml
  44. https://www.erowid.org/library/books_online/tihkal/tihkal06.shtml
  45. https://erowid.org/library/books_online/tihkal/tihkal06.shtml
  46. https://www.erowid.org/library/books_online/tihkal/tihkal38.shtml
  47. https://www.erowid.org/library/books_online/tihkal/tihkal17.shtml
  48. https://www.amazon.com/Tihkal-Continuation-Alexander-Shulgin/dp/0963009699
  49. https://synergeticpress.com/catalog/tihkal-the-continuation/
  50. https://www.bionity.com/en/encyclopedia/Alpha-Methyltryptamine.html
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC4211607/
  52. https://pubs.acs.org/doi/10.1021/acsptsci.0c00176
  53. https://www.researchgate.net/figure/of-Shulgins-early-findings-on-structural-modifications-and-their-relation-to_fig3_337602798
  54. https://pubmed.ncbi.nlm.nih.gov/29499272/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/
  56. https://mdma.net/alexander-shulgin/21stc.html
  57. https://doubleblindmag.com/sasha-shulgin-legacy/
  58. https://www.muckrock.com/news/archives/2016/jun/23/shulgin-dea/
  59. https://www.ricardinis.pt/wp-content/uploads/2017/01/Metabolism-of-psilocybin-and-psilocin-clinical-and-forensic-toxicological-relevance.pdf
  60. https://www.lucid.news/on-drugs-freedom-and-human-nature-a-course-with-alexander-shulgin/
  61. https://www.unodc.org/pdf/report_2001-06-26_1/analysis_clandestine.pdf
  62. https://drugabuserecognition.com/the-drug-enforcers-reading-list/
  63. https://samizdathealth.org/wp-content/uploads/2020/12/Shulgin-2.pdf
  64. https://realitysandwich.com/second-psychedelic-revolution-part-two/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC4462041/
  66. https://www.researchgate.net/publication/275022240_Recreational_Use_Analysis_and_Toxicity_of_Tryptamines
  67. https://academic.oup.com/jat/article-pdf/29/8/838/2120103/29-8-838.pdf
  68. https://www.sciencedirect.com/science/article/abs/pii/S2352007815002619
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC5870365/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC6995261/
  71. https://www.theguardian.com/science/from-the-archive-blog/2014/jun/03/shulgin-alexander-drugs-ecstasy-mdma
  72. https://www.sciencedirect.com/science/article/pii/S0028390818302296
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC7880300/
  74. https://www.researchgate.net/publication/5486380_Research_Chemicals_Tryptamine_and_Phenethylamine_Use_Among_High-Risk_Youth
  75. https://www.researchgate.net/publication/378039602_Effects_of_DMT_on_mental_health_outcomes_in_healthy_volunteers
  76. https://journals.sagepub.com/doi/abs/10.1177/02698811211069100
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC3056407/
  78. https://psychiatryonline.org/doi/10.1176/appi.ajp.20230902
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC11338697/
  80. https://patents.google.com/patent/EP3844147B1/en
  81. https://patents.justia.com/patent/20210395201
  82. https://www.science.org/doi/10.1126/science.abl8615
  83. https://maps.org/1999/04/01/human-psychedelic-research-a-historical-and-sociological-analysis/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC10845102/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC11387584/
  86. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.1686
  87. https://psychedelicalpha.com/data/psychedelic-laws
  88. https://www.nature.com/articles/s41386-023-01656-7
Add your contribution
Related Hubs
User Avatar
No comments yet.